Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Markman on the Search for Actionable Biomarkers in Ovarian Cancer

January 5th 2017

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the search for actionable biomarkers in the treatment of patients with ovarian cancer.

FDA Grants Niraparib Priority Review in Ovarian Cancer

December 20th 2016

The FDA has granted a priority review to a new drug application for the PARP 1/2 inhibitor niraparib for use as a maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded to platinum-based chemotherapy.

Dr. Birrer on FDA Approval of Rucaparib in Ovarian Cancer

December 19th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the FDA approval of rucaparib for as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy.

FDA Approves Rucaparib for Ovarian Cancer

December 19th 2016

The FDA has approved rucaparib (Rubraca) as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy, according to Clovis, the manufacturer of the PARP inhibitor

Expert Says Biomarkers Top Priority for Immunotherapy Progress in Ovarian Cancer

December 13th 2016

Although randomized phase III clinical trials often lead to groundbreaking drug approvals and offer novel therapeutic regimens, Maurie Markman, MD, insists that the search for validated, actionable biomarkers is more important than initiation of new studies.

FDA Approves Bevacizumab for Platinum-Sensitive Ovarian Cancer

December 7th 2016

Bevacizumab has been granted FDA approval for platinum-sensitive ovarian cancer, based on findings from phase III trails: GOG-0213 and OCEANS.

Moving the Meter on Ovarian Cancer

December 2nd 2016

Ovarian cancer remains a silent and deadly tumor type with 5-year survival rates that lag far behind those of other gynecologic malignancies. Yet optimism is in the air these days as researchers focus on developing new therapies in 2 key areas: antiangiogenic agents and PARP inhibitors.

Novel Agent Anchors Triplet Regimen in Ovarian Cancer Trial

December 1st 2016

A multipronged attack on the tumor vasculature network is at the heart of a recently launched clinical trial aimed at developing new therapeutic options for women with advanced, recurrent, platinum-resistant ovarian cancer.

Dr. Mirza on Impact of Niraparib in Ovarian Cancer

November 30th 2016

Mansoor Raza Mirza, MD, chief oncologist at Rigshospitalet, Copenhagen, Denmark, discusses niraparib in patients with platinum-sensitive recurrent ovarian cancer

Levine Sheds Light on Precision Medicine in Gynecologic Malignancies

November 28th 2016

Significant progress is being made in the treatment of gynecologic malignancies, especially in ovarian cancer, according to Douglas A. Levine, MD.

Dr. Jasgit Sachdev on What's on the Horizon for Ovarian Cancer

November 23rd 2016

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses the goals she would like to see achieved regarding the treatment of ovarian cancer.

Dr. Muggia on Combination Treatments in Ovarian Cancer

November 23rd 2016

Franco M. Muggia, MD, professor, Department of Medicine, NYU Langone Medical Center, discusses combination treatments currently being tested for the treatment of patients with ovarian cancer.

Susan Lutgendorf on Impact of Minimal Support on Patients With Ovarian Cancer

November 16th 2016

Susan Lutgendorf, PhD, professor and Starch Faculty Fellow, Psychological and Brain Sciences, College of Liberal Arts and Sciences, University of Iowa, discusses the impact of lack of support on patients with ovarian cancer. Lutgendorf spoke on this during an interview at the SITC 31st Annual Meeting and Associated Programs.

PARP Inhibition at the Forefront of Ovarian Cancer Treatment Paradigm

November 15th 2016

PARP inhibition is quickly becoming a major element of the overall ovarian cancer treatment landscape, as several of these agents are continuing to advance through clinical development.

Patient Selection Critical to Optimizing Neoadjuvant Chemo in Ovarian Cancer

November 11th 2016

As a treatment of patients with advanced ovarian cancer, evidence has shown that neoadjuvant chemotherapy has reduced mortality and improved quality of life. However, oncologists are still challenged at how to deploy this treatment approach in clinical practice.

Dr. Markman on Immune Targeting in Ovarian Cancer

November 10th 2016

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the current status of immune targeting as potential treatment for patients with ovarian cancer.

FDA Submission Completed for Niraparib in Ovarian Cancer

November 2nd 2016

A new drug application to the FDA has been completed for niraparib as a maintenance treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

Maintenance Olaparib Improves PFS in Phase III Ovarian Cancer Trial

October 26th 2016

Single-agent olaparib significantly improved progression-free survival compared with placebo in the maintenance setting for patients with advanced BRCA-positive ovarian cancer.

Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian Cancer

October 25th 2016

Results from an expansion cohort of a preliminary clinical trial have shown encouraging activity for a novel antibody-drug conjugate in patients with heavily pretreated advanced ovarian cancer.

Niraparib Expected to Change Practice in Ovarian Cancer

October 19th 2016

The PARP1/2 inhibitor niraparib significantly improved progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.